

# Shaohong Peng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6821365/publications.pdf>

Version: 2024-02-01

8  
papers

254  
citations

1307594  
7  
h-index

1588992  
8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

338  
citing authors

| # | ARTICLE  | IF   | CITATIONS |
|---|--|------|-----------|
| 1 | Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1. <i>Journal of the American Chemical Society</i> , 2015, 137, 14180-14189.  | 13.7 | 106       |
| 2 | Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8709-8714.      | 7.1  | 39        |
| 3 | A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a <i>Drosophila</i> Model of Myotonic Dystrophy. <i>ChemMedChem</i> , 2016, 11, 1428-1435.           | 3.2  | 36        |
| 4 | Integrating Display and Delivery Functionality with a Cell Penetrating Peptide Mimic as a Scaffold for Intracellular Multivalent Multitargeting. <i>Journal of the American Chemical Society</i> , 2016, 138, 9498-9507. | 13.7 | 26        |
| 5 | CAG RNAs induce DNA damage and apoptosis by silencing <i>NUDT16</i> expression in polyglutamine degeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .      | 7.1  | 17        |
| 6 | A peptidyl inhibitor-based therapeutic approach that simultaneously suppresses RNA- and protein-mediated toxicities in polyglutamine diseases. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 321-34.               | 2.4  | 14        |
| 7 | Pharmacokinetics and brain uptake of HIV-1 replication inhibitor DB213 in Sprague-Dawley rats. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 125, 41-47.  | 2.8  | 10        |
| 8 | Efficient brain uptake and distribution of an expanded CAG RNA inhibitor DB213 via intranasal administration. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 240-251.                                   | 4.0  | 6         |